Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 37 | ECE2015 | Next issue

17th European Congress of Endocrinology


Management of type 2 diabetes: State of the art

ea0037s2.1 | Management of type 2 diabetes: State of the art | ECE2015

Blood pressure management in Type 2 Diabetes Mellitus

Rossing Peter

Hypertension is a major risk factor in type 2 diabetes both for cardiovascular and microvascular complications. It has been estimated that hypertension contributes to 41% of the attributable risk for mortality. Proper assessment of blood pressure, consideration of diurnal pattern, white coat and masked hypertension is important. Lifestyle factors should be addressed in the management, but in most patients pharmaceutical intervention is needed. The optimal intervention usually ...

ea0037s2.2 | Management of type 2 diabetes: State of the art | ECE2015

Blood glucose management

Birkeland Kare

Glucose lowering treatment in patients with type 2 diabetes aims at reducing hyperglycaemic symptoms, preventing acute hyperglycaemic crisis and delaying the onset and progression of microvascular complications. The impact of glucose control on cardiovascular complications remains uncertain, however, a modest benefit is likely to be present.The cornerstones of treatment remain education, motivation and counseling on healthy eating behavior and moderate p...

ea0037s2.3 | Management of type 2 diabetes: State of the art | ECE2015

PCSK9 antibodies for the treatment of hypercholesterolemia

Gouni-Berthold Ioanna

Cardiovascular disease (CVD) is the leading cause of death worldwide accounting for more than 17 million deaths just in 2012. A major culprit for the development of CVD is an elevated low density lipoprotein (LDL) cholesterol (LDL-C) concentration. Despite statin therapy a high residual risk of cardiovascular events remains, especially since with the currently available treatment options only ~50% of high risk patients and ~20% of very high risk patients achieve their target L...